American Journal of Clinical Oncology 2003-08-01

A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer.

Randolph S Marks, David L Graham, Jeff A Sloan, Shauna Hillman, Steven Fishkoff, James E Krook, Scott H Okuno, James A Mailliard, Tom R Fitch, Ferdinand Addo

Index: Am. J. Clin. Oncol. 26(4) , 336-7, (2003)

Full Text: HTML

Abstract

A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.